Advertisement

Tumor Biology

, Volume 35, Issue 3, pp 1745–1749 | Cite as

Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis

  • Yanfeng Zhuang
  • Meiyang Wei
Research Article

Abstract

Osteosarcoma is the most common primary malignant bone tumor of childhood. Vascular endothelial growth factor (VEGF) expression has been implicated in tumor development and progression of osteosarcoma, but previous studies investigating the impact of VEGF expression on overall survival in patients with osteosarcoma report conflicting findings. A meta-analysis of published studies was performed. The pooled hazard ratio (HR) with its 95 % confidence interval (95 % CI) was used to assess the impact of VEGF expression on overall survival in patients with osteosarcoma. Nine studies with a total of 432 osteosarcoma patients were included into this meta-analysis. There was no between-study heterogeneity among those nine studies (I 2 = 0.0 %). Overall, high VEGF expression was obviously associated with poorer overall survival (HR = 1.68, 95 % CI 1.33–2.12, P < 0.001). Sensitivity analysis performed by excluding single study in turns showed the pooled estimate was stable. Egger’s test also did not suggest evidence for publication bias (P = 0.216). Therefore, this meta-analysis suggests that VEGF expression has an important impact on overall survival in patients with osteosarcoma and high VEGF expression is associated with poorer overall survival.

Keywords

Vascular endothelial growth factor Osteosarcoma Prognosis 

Notes

Conflicts of interest

The authors declare no competing financial interests.

References

  1. 1.
    Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol. 2005;6:85–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60:222–43.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.PubMedCrossRefGoogle Scholar
  5. 5.
    Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med. 2011;32:88–111.PubMedCrossRefGoogle Scholar
  6. 6.
    Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27:563–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6:572–7.PubMedGoogle Scholar
  8. 8.
    Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics. 2005;28:755–60.PubMedGoogle Scholar
  9. 9.
    Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer. 2009;53:1035–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Lin F, Zheng SE, Shen Z, Tang LN, Chen P, Sun YJ, et al. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol. 2011;28:649–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011;117:4925–38.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Rastogi S, Kumar R, Sankineani SR, Marimuthu K, Rijal L, Prakash S, et al. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study. Int Orthop. 2012;36:2315–21.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  15. 15.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res. 2006;448:193–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Chen GL, Lin HB, Wu XW, Li RY, Chen XH. The correlation between the level of serum vegf and bfgf with metastasis and prognosis of osteosarcoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011;27:1343–5.PubMedGoogle Scholar
  20. 20.
    Lugowska I, Wozniak W, Klepacka T, Michalak E, Szamotulska K. A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatr Blood Cancer. 2011;57:63–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320–325.PubMedGoogle Scholar
  22. 22.
    Korpi JT, Hagstrom J, Lehtonen N, Parkkinen J, Sorsa T, Salo T, et al. Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol. 2011;20:e18–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Masrouha KZ, Khattab R, Tawil A, Abdallah A, Saghieh S, Haidar R, et al. A preliminary investigation of beta-hCG expression in patients with osteosarcoma. J Bone Joint Surg Br. 2012;94:419–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Chen Y, Zhang L, Pan Y, Ren X, Hao Q. Over-expression of semaphorin4D, hypoxia-inducible factor-1α and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. Int J Mol Sci. 2012;13:13264–74.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Guo JH, Zhu X, Li XT, Yang RJ. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chin J Cancer Res. 2012;24:36–43.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Hong KD, Lee Y, Kim BH, Lee SI, Moon HY. Expression of GLI1 correlates with expression of lymphangiogenesis proteins, vascular endothelial growth factor c and vascular endothelial growth factor receptor 3, in colorectal cancer. Am Surg. 2013;79:198–204.PubMedGoogle Scholar
  27. 27.
    Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and vegf expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94:1823–32.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4:1094–103.PubMedCrossRefGoogle Scholar
  29. 29.
    Chen M, Cai E, Huang J, Yu P, Li K. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:1126–34.PubMedCrossRefGoogle Scholar
  30. 30.
    Liu L, Ma XL, Xiao ZL, Li M, Cheng SH, Wei YQ. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer Prev. 2012;13:3089–97.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Orthopedics DepartmentFuzhou General Hospital of Nanjing MilitaryFuzhouChina

Personalised recommendations